As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works best has gained importance.

Omalizumab demonstrates superior symptom control in CSU, with 34%-44% achieving complete control in phase 3 trials. Dupilumab, an IL-4Rα antagonist, shows efficacy in CSU, particularly for patients ...

The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous ...